beth israel deaconess medical center a harvard medical school teaching hospital

To find a doctor, call 800-667-5356 or click below:

Find a Doctor

Request an Appointment

left banner
right banner
Smaller Larger

Program for Psychosis Risk Assessment in Youth and Early Remediation

Matcheri Keshavan, M.D.
Stanley Cobb Professor of Psychiatry;
Harvard Medical School
Vice Chair of Public Psychiatry;
Beth Israel Deaconess Medical Center
Massachusetts Mental Health Center

As part of a major new research initiative, Dr. Matcheri Keshavan joined the faculty of the BIDMC Department of Psychiatry in 2008.  Dr. Keshavan's work focuses on neurobiological models of schizophrenia and on the development and implementation of early interventions with biopsychosocial treatment strategies. 

Dr. Keshavan is one of the Principal Investigators of the Bipolar Disorders and Schizophrenia Network on Intermediate Phenotypes (B-SNIP), a six site NIH funded study which is investigating the unique versus distinct biomarkers in these two major mental disorders.  Additionally,  Dr. Keshavan is leading an ongoing NIH funded longitudinal study in Pittsburgh and Detroit to characterize premorbid predictors of psychosis in adolescents at genetic risk.  His group plans to continue these lines of work at BIDMC as part of his research program. 

Another line of investigation by Dr. Keshavan seeks to further refine and test a novel approach to cognitive remediation initially developed by his collaborators in Pittsburgh in early course schizophrenia patients.  A recently funded study will evaluate the effectiveness of a computer based Brain Fitness Program in improving cognitive deficits in patients with schizophrenia at the Massachusetts Mental Health Center. 

Dr. Keshavan's responsibilities include the development of a thriving research program focused on psychotic disorders, and mentoring psychiatry residents, other trainees, and faculty into research careers.  The Department is currently recruiting nationally three or more additional psychiatric investigators as part of Dr. Keshavan's program.